<DOC>
	<DOCNO>NCT00146341</DOCNO>
	<brief_summary>To demonstrate fix dose combination telmisartan 80 mg plus HCTZ 12.5 mg superior telmisartan 80 mg alone patient , fail respond adequately telmisartan 80 mg monotherapy , lower seat trough diastolic blood pressure eight week treatment .</brief_summary>
	<brief_title>Combination Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg Telmisartan 80 mg Patients Failed Telmisartan 80 mg</brief_title>
	<detailed_description>This multi-centre , prospective , randomize , double-blind , parallel-group study approximately 244 patient history mild-to-moderate hypertensive show respond telmisartan monotherapy . All patient enter one-week screening phase prior start eight-week open-label T80 mg period . At end four week , patient fail respond T80 mg ( DBP &gt; = 90 mm Hg ) continue treatment T80 mg another four week . At end eight week , patient fail respond T80 mg ( DBP &gt; = 90 mm Hg ) randomize , double-blind , receive either T80 mg alone fix dose combination T80 mg plus HCTZ 12.5 mg eight week . Seated BP take 24 hour post-dose visit . Labs , ECG , physical examination do screening , baseline final visit . Study Hypothesis : The primary objective study , show fix dose combination superior telmisartan 80 mg alone test use hypothesis give . H0 : u T80/H12.5 - uT80 = 0 mm Hg versus H1 : uT80/H12.5 - uT80 equal 0 mm Hg , uT80/H12.5 anduT80 represent average reduction baseline ( Visit 4 ) trough seat DBP fix dose combination telmisartan 80 mg , respectively . Testing null hypothesis perform use two-sided test significance a-level ( type-I error rate ) 0.05 . Comparison ( ) : The primary efficacy endpoint change baseline seat DBP 24 hour post-dose last visit double-blind treatment phase . The pre-dose measurement visit 4 view baseline measurement .</detailed_description>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . History mildtomoderate hypertension define mean seated DBP &gt; =95 &lt; = 109 mmHg inclusion openlabel phase 2 . Patients fail respond adequately telmisartan monotherapy ( mean seat DBP &gt; = 90 mmHg ) 3 . Participants 18 80 year age 4 . Ability provide write informed consent 1 . Patients take three antihypertensive medication screen visit . 2 . Premenopausal woman ( last menstruation 1 year prior start screen ) : Who surgically sterile ( hysterectomy , tubal ligation ) Who NOT practice acceptable mean birth control NOT plan continue use acceptable method throughout study ( acceptable method birth control include IUD , oral , implantable injectable contraceptive ) 3 . Any woman : Who positive urine pregnancy test screening ( Visit 1 ) Who nurse 4 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) great two time upper limit normal Serum creatinine &gt; 3.0 mg/dL ( 265 mol/L ) creatinine clearance &lt; 0.6 ml/sec 5 . Clinically relevant hypokalaemia hyperkalaemia 6 . Uncorrected volume depletion 7 . Uncorrected sodium depletion 8 . Primary aldosteronism 9 . Hereditary fructose intolerance 10 . Biliary obstructive disorder , cholestasis moderate severe hepatic insufficiency 11 . Known suspected secondary hypertension 12 . Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant patient , presence one functioning kidney 13 . Congestive heart failure ( NYHA functional class CHF IIIIV ) 14 . Unstable angina within past three month 15 . Stroke within past six month 16 . Myocardial infarction cardiac surgery within past three month 17 . PTCA within past three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>